XM does not provide services to residents of the United States of America.
G
G

Givaudan

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Allianz SE, Halma, ITM Power

EUROPE RESEARCH ROUNDUP-Allianz SE, Halma, ITM Power Feb 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz SE, Halma and ITM Power Plc on Monday. HIGHLIGHTS * Allianz SE ALVG.DE : JP Morgan raises target price to EUR 275 from EUR 270 * Halma HLMA.L : HSBC cuts to hold from buy * ITM Power Plc ITM.L : Jefferies raises to buy from hold * Nel ASA NEL.OL : Jefferies cuts to hold from buy * Orion Oyj ORNBV.HE : Jefferies cuts t
A
A
B
B
B
B
B
C
C
D
E
E
E
F
G
G
G
H
L
R
S
S
T
A
A
A
A
A
A
B

IFF slips on dour FY forecast, brokerages cut PT

BUZZ-IFF slips on dour FY forecast, brokerages cut PT ** Shares of International Flavors & Fragrances IFF.N fall about 6% to $77.16 in early hours, their lowest since Dec 13 ** After markets closed on Tuesday, the chemicals company forecast FY sales below estimates and took a $2.6 bln charge on its nourish segment ** Stifel brokerage cuts PT to $80
G
S
I

Flavour and fragrance makers slip on U.S. peer's outlook

BUZZ-Flavour and fragrance makers slip on U.S. peer's outlook ** Shares in flavour and fragrance makers Symrise SY1G.DE and Givaudan GIVN.S slip 1.65% and 1%, respectively, after U.S. rival International Flavors & Fragrances (IFF) forecast annual sales below market expectations ** Oliver Schwarz from Warburg Research says IFF's dissappointing outlo
G
S
S
I
G

DSM’s China de-risking plan hinges on booster shot

BREAKINGVIEWS-DSM’s China de-risking plan hinges on booster shot The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphic. By Karen Kwok LONDON, Feb 15 (Reuters Breakingviews) - DSM-Firmenich’s DSFIR.AS plan to break off its animal supplements business hinges on it receiving a much-needed booster shot.
B
G

Firmenich to carve out animal nutrition and health business in 2025

UPDATE 3-DSM-Firmenich to carve out animal nutrition and health business in 2025 Adds share reaction in paragraph 2, outlook and dividend in 10-12 By Tristan Veyet and Mateusz Dobrzyniewski Feb 15 (Reuters) - DSM-Firmenich DSFIR.AS on Thursday said it plans to separate its animal nutrition and health business from the group next year, as the Dutch-listed chemicals company aims to sharpen its focus on the nutrition, health, and beauty segments.
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.